Approved lymphoma drug shows promise in early tests against bone cancer

09-Nov-2009 - A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in ...

Research and Markets: Company and Industry Analysis of the US $ 14.9 Billion Asia-Pacific Biotechnology Market

10-Oct-2008 - Research and Markets has announced the addition of the "Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis" report to their offering. This report updates the previous Asia-Pacific biotechnology report, focusing on the markets in Australia, China and Hong Kong, India, Japan, ...

Dharmacon to deliver First Whole Human Genome-Wide siRNA Library

18-May-2005 - Dharmacon, Inc. announced an agreement to deliver a genome-wide short-interfering RNA (siRNA) library covering approximately 22.000 human genes to Millennium Pharmaceuticals, Inc. This library, the first siRNA collection targeting genes across the entire human genome, was developed using ...

Millennium Announces Promising Findings from Novel Antibody-Chemotherapeutic

22-Feb-2005 - Millennium Pharmaceuticals, Inc. announced final results from a phase I clinical trial of MLN2704 in patients with advanced hormone-refractory prostate cancer. These results were presented at the 2005 Prostate Cancer Symposium taking place this week in Orlando, Fl. The findings from this first ...

Millennium and NCI Collaborate to Investigate Role of ACE2 in Connection with SARS

Recent publications identify connection between genomic target and deadly virus

02-Apr-2004 - Cambridge, Mass. Millennium Pharmaceuticals, Inc. announced it is collaborating with the National Cancer Institute (NCI) to study the link between the novel enzyme angiotensin-converting enzyme 2 (ACE2) and the virus that causes severe acute respiratory syndrome (SARS). "We are excited that the ...

Millennium In-Licenses Novel Oncology Program from Xenova

18-Dec-2001 - CAMBRIDGE, Mass., and SLOUGH, U.K., December 17, 2001 - Millennium Pharmaceuticals, Inc. and Xenova Group, plc announced that the companies have signed a license agreement for the development and North American commercialization of Xenova?s novel compounds, which have a unique mechanism of action ...

New Phase II Data on Millennium's Proteasome Inhibitor Holds Promise for Patients with Refractory Multiple Myeloma

11-Dec-2001 - Cambridge, MA, December 10, 2001 - Millennium Pharmaceuticals, Inc. announced today preliminary findings of an ongoing phase II clinical trial of its investigational drug LDP-341 (formerly known as PS-341) in patients with multiple myeloma who have failed to respond to other treatments. The study ...

Millennium and COR Therapeutics Agree to Merge, Creating Integrated Biopharmaceutical Company

07-Dec-2001 - Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. today announced that they have signed a definitive agreement for Millennium to acquire COR in a stock-for-stock exchange valued at $2.0 billion. The combined company will be named Millennium Pharmaceuticals, Inc., with worldwide ...

Millennium and Abbott Initiate Phase I Trials of their First Genomically-Derived Drug Target for Obesity

28-Nov-2001 - CAMBRIDGE, Mass., and ABBOTT PARK, Ill., November 27, 2001 - Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Abbott Laboratories, (NYSE: ABT) today announced the initiation of a Phase I clinical trial of MLN4760. This represents the first molecule directed against a genomically-derived target ...